医学
肝性脑病
内科学
肝硬化
萧条(经济学)
共病
糖尿病
肝病
胃肠病学
逻辑回归
经济
宏观经济学
内分泌学
作者
Chathur Acharya,Omar Nadhem,Jawaid Shaw,Ramzi Hassouneh,Andrew Fagan,Sara McGeorge,Richard K. Sterling,Prem Puri,Michael Fuchs,Velimir A. Luketic,Arun J. Sanyal,James B. Wade,HoChong Gilles,Douglas M. Heuman,Felicia Tinsley,Scott Matherly,Hannah Lee,Mohammad Shadab Siddiqui,Leroy R. Thacker,Jasmohan S. Bajaj
标识
DOI:10.14309/ajg.0000000000001346
摘要
We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development.Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84% men, model for end-stage liver disease 11) and 33% prior OHE underwent testing and follow-up.Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables.Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI